Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Rotork Q1 revenues seen 'modestly lower'

(Sharecast News) - Industrial flow components manufacturer Rotork said on Friday that Q1 revenues had slipped despite reporting increased order intake during the period. Rotork said revenues were "modestly lower year-on-year" in the quarter, reflecting order book phasing and a strong comparator, even as order intake was said to be up mid-single digits year-on-year.

The FTSE 250-listed group stated all of its divisions achieved higher orders year-on-year, with water and power delivering the highest growth. Orders from the LNG liquefaction sector were "strongly ahead" year-on-year.

Rotork also noted that its three North American facilities, which together represent around a fifth of group sales, were all located in the US and had the capacity to supply the majority of local demand. Additionally, to cover incremental costs arising from higher tariffs, Rotork said it had implemented a surcharge increase.

Looking forward, Rotork stated there has been "no significant change in order trends or customer behaviour" since the publication of its FY24 results and said April trading was in line with internal expectations.

"Whilst we are mindful of ongoing macro uncertainty, we continue to expect 2025 to be a year of progress on an OCC basis supported by our order book and positive end markets," said Rotork.

As of 0825 GMT, Rotork shares were down 1.90% at 299.20p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.